Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial*

BACKGROUND AND STUDY AIMS The AIM-II Trial included patients with nondysplastic Barrett's esophagus (NDBE) treated with radiofrequency ablation (RFA). Complete eradication of NDBE (complete response-intestinal metaplasia [CR-IM]) was achieved in 98.4 % of patients at 2.5 years. We report the proportion of patients demonstrating CR-IM at 5-year follow-up. PATIENTS AND METHODS Prospective, multicenter US trial (NCT00489268). After endoscopic RFA of NDBE up to 6 cm, patients with CR-IM at 2.5 years were eligible for longer-term follow-up. At 5 years, we obtained four-quadrant biopsies from every 1 cm of the original extent of Barrett's esophagus. All specimens were reviewed by one expert gastrointestinal pathologist, followed by focal RFA and repeat biopsy if NDBE was identified. Primary outcomes were (i) proportion of patients demonstrating CR-IM at 5-year biopsy, and (ii) proportion of patients demonstrating CR-IM at 5-year biopsy or after the single-session focal RFA. RESULTS Of 60 eligible patients, 50 consented to participate. Of 1473 esophageal specimens obtained at 5 years 85 % contained lamina propria or deeper tissue (per patient, mean 30 , standard deviation [SD] 13). CR-IM was demonstrated in 92 % (46 / 50) of patients, while 8 % (4 / 50) had focal NDBE; focal RFA converted all these to CR-IM. There were no buried glands, dysplasia, strictures, or serious adverse events. Kaplan-Meier CR-IM survival analysis showed probability of maintaining CR-IM for at least 4 years after first durable CR-IM was 0.91 (95 % confidence interval [CI] 0.77 - 0.97) and mean duration of CR-IM was 4.22 years (standard error [SE] 0.12). CONCLUSIONS In patients with NDBE treated with RFA, CR-IM was demonstrated in the majority of patients (92 %) at 5-year follow-up, biopsy depth was adequate to detect recurrence, and all failures (4 / 4, 100 %) were converted to CR-IM with single-session focal RFA.

[1]  J. Hunter,et al.  W1876 Are Biopsies After Ablation for Dysplastic Barrett's Esophagus of Adequate Depth to Detect Glandular Mucosa Beneath the Neosquamous Epithelium? - Comparative Histopathological Outcomes from a Randomized, Sham-Controlled Trial (Aim Dysplasia Trial) , 2008 .

[2]  H. Fernando,et al.  Radiofrequency ablation for Barrett's esophagus and low-grade dysplasia in combination with an antireflux procedure: a new paradigm. , 2010, The Journal of thoracic and cardiovascular surgery.

[3]  V. Velanovich,et al.  Endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus in patients with fundoplications , 2007, Surgical Endoscopy.

[4]  V. Velanovich.  Endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus: initial results and lessons learned , 2009, Surgical Endoscopy.

[5]  P. Fockens,et al.  Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system , 2008, Endoscopy.

[6]  Kenneth K Wang,et al.  Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.

[7]  R. Sandler,et al.  Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. , 2002 .

[8]  A. Gavin,et al.  Mortality in Barrett’s oesophagus: results from a population based study , 2003, Gut.

[9]  J. de Caestecker,et al.  Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: factors determining persistence and recurrence of Barrett’s epithelium , 2002, Gut.

[10]  M. Crowell,et al.  An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett’s esophagus , 2009, Endoscopy.

[11]  Paul Fockens,et al.  Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  D. Fleischer,et al.  A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). , 2008, Endoscopy.

[13]  Prateek Sharma,et al.  Endoscopic eradication of Barrett's esophagus. , 2010, Gastrointestinal endoscopy.

[14]  Bergein F Overholt,et al.  Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. , 2007, Gastrointestinal endoscopy.

[15]  Kenneth J. Chang,et al.  Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. , 2008, Gastrointestinal endoscopy.

[16]  R. Sampliner,et al.  Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  J. Inadomi.  Surveillance in Barrett's esophagus: a failed premise. , 2009, The Keio journal of medicine.

[18]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.

[19]  D. Sautereau,et al.  French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett’s esophagus , 2007, Endoscopy.

[20]  P. Fockens,et al.  Stepwise circumferential and focal ablation of Barrett’s esophagus with high-grade dysplasia: results of the first prospective series of 11 patients , 2008, Endoscopy.

[21]  D. Chung,et al.  Pilot series of radiofrequency ablation of Barrett's esophagus with or without neoplasia. , 2008, Endoscopy.

[22]  B. Overholt,et al.  Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. , 2007, Gastrointestinal endoscopy.

[23]  A. Neugut,et al.  Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  A. Ippoliti,et al.  Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. , 2005, Gastrointestinal endoscopy.

[25]  R. K. Pearson.  Radiofrequency Ablation in Barrett's Esophagus with Dysplasia , 2009 .

[26]  Janusz Jankowski,et al.  A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. , 2004, Gastroenterology.

[27]  N. Nishioka,et al.  Histopathologic Aspects of Photodynamic Therapy for Dysplasia and Early Adenocarcinoma Arising in Barrett’s Esophagus , 2004, The American journal of surgical pathology.

[28]  R. Fitzgerald.  Complex diseases in gastroenterology and hepatology: GERD, Barrett's, and esophageal adenocarcinoma. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  R. Sandler,et al.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.

[30]  J K Greenson,et al.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. , 2001, Human pathology.

[31]  L. Hardie,et al.  Biomarkers in Barrett's oesophagus. , 2010, Biochemical Society transactions.

[32]  A. Bhattacharyya,et al.  Squamous Islands in Barrett's Esophagus: What Lies Underneath? , 1998, American Journal of Gastroenterology.

[33]  S. Force,et al.  Radiofrequency ablation of Barrett's esophagus: short-term results. , 2009, The Annals of thoracic surgery.

[34]  Kenneth J. Chang,et al.  Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. , 2008, Gastrointestinal endoscopy.

[35]  A. Rastogi,et al.  Esophageal Adenocarcinoma in Barrett's Esophagus After Endoscopic Ablative Therapy: A Meta-Analysis and Systematic Review , 2009, The American Journal of Gastroenterology.

[36]  R. Turell.  Society for Surgery of the Alimentary Tract , 1966 .

[37]  A. Tsykin,et al.  MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma , 2010, The British journal of surgery.

[38]  O. Cummings,et al.  Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. , 1999, Gastrointestinal endoscopy.

[39]  Gary Longton,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets , 2000, American Journal of Gastroenterology.

[40]  P. Fockens,et al.  Eradication of Barrett Esophagus with Early Neoplasia by Radiofrequency Ablation, with or without Endoscopic Resection , 2008, Journal of Gastrointestinal Surgery.

[41]  N. Shaheen,et al.  A cost-utility analysis of ablative therapy for Barrett's esophagus. , 2009, Gastroenterology.

[42]  R. Haggitt,et al.  Barrett's esophagus, dysplasia, and adenocarcinoma. , 1994, Human pathology.

[43]  A. Bhattacharyya,et al.  Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. , 1999, Gastrointestinal endoscopy.

[44]  Patricia L. Blount,et al.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables , 2001, American Journal of Gastroenterology.

[45]  Ananya Das,et al.  Circumferential and Focal Ablation of Barrett's Esophagus Containing Dysplasia , 2009, The American Journal of Gastroenterology.

[46]  P. Mavrelis,et al.  Radiofrequency ablation of Barrett’s esophagus: outcomes of 429 patients from a multicenter community practice registry , 2010, Endoscopy.